

UC Davis

UC Davis Previously Published Works

Title

Effect of the WeCareAdvisor™ on family caregiver outcomes in dementia: a pilot randomized controlled trial.

Permalink

<https://escholarship.org/uc/item/0vf5r76h>

Journal

BMC geriatrics, 18(1)

ISSN

1471-2318

Authors

Kales, Helen C
Gitlin, Laura N
Stanislawski, Barbara
et al.

Publication Date

2018-05-01

DOI

10.1186/s12877-018-0801-8

Peer reviewed

RESEARCH ARTICLE

Open Access



Effect of the WeCareAdvisor™ on family caregiver outcomes in dementia: a pilot randomized controlled trial

Helen C. Kales^{1,2,3*} , Laura N. Gitlin^{4,5,6}, Barbara Stanislawski^{1,2}, H. Myra Kim⁷, Katherine Marx⁶, Molly Turnwald¹, Claire Chiang^{1,2} and Constantine G. Lyketsos⁸

Abstract

Background: Behavioral and psychological symptoms of dementia (BPSD) are universal and associated with multiple negative outcomes. This pilot randomized controlled trial (RCT) evaluated the effect of using the WeCareAdvisor, an innovative web-based tool developed to enable family caregivers to assess, manage, and track BPSD.

Methods: This RCT enrolled 57 dementia family caregivers from community and clinical settings in Ann Arbor, Michigan and Baltimore, Maryland. Participants were randomly assigned to immediate use of the WeCareAdvisor tool (WCA, $n = 27$) or a Waitlist control group ($n = 30$) that received the tool after a one-month waiting period. Outcomes for the caregiver and the person they were caring for were assessed at baseline (T0) and one-month followup for both the WCA (T1) and Waitlist control (T2) groups.

Results: Caregiver mean age was 65.9 ± 14.0 years old. About half (49%) were spouses. Baseline characteristics were comparable between groups except for mean caregiver confidence which was higher in the control group (WCA 35.0 ± 10.0 vs. Waitlist control 39.7 ± 6.9 , $p = 0.04$). There were no significant differences between the WCA and control groups in characteristics of the person with dementia. After their one-month of tool use (T1), WCA caregivers showed significant within group improvement in caregiver distress (-6.08 ± 6.31 points, $t = -4.82$, $p < 0.0001$) and behavioral frequency (-3.60 ± 5.05 , $t = -3.56$, $p = 0.002$), severity (-3.24 ± 3.87 , $t = -4.19$, $p = 0.0003$) and total behavioral score (-6.80 ± 10.73 , $t = -3.17$, $p = 0.004$). In the same timeframe, Waitlist control caregivers showed a significant decrease in confidence (-6.40 ± 10.30 , $t = -3.40$, $p = 0.002$). The WCA group showed greater improvement in distress compared to the Waitlist group (T0-T1; $t = -2.49$, $p = 0.02$), which remained significant after adjusting for site and baseline distress. There were no significant between-group differences in caregiver confidence or other secondary outcomes. After their one month of tool use (T2), the Waitlist group also showed significant improvement in caregiver distress (-3.72 ± 7.53 , $t = -2.66$, $p = 0.013$), stress (-0.41 ± 1.02 , $t = -2.19$, $p = 0.037$), confidence (4.38 ± 5.17 , $t = 4.56$, $p < 0.0001$), burden (-2.76 ± 7.26 , $t = -2.05$, $p = 0.05$), negative communication (-1.48 ± 2.96 , $t = -2.70$, $p = 0.012$) and behavioral frequency (-1.86 ± 4.58 , $t = -2.19$, $p = 0.037$); distress remained significant after adjustment.

Conclusions: In this pilot RCT, WCA use resulted in a significant decrease in caregiver distress. Future research will identify whether longer use of WCA can impact other caregiver and behavioral outcomes.

Trial registration: [Clinicaltrials.gov](https://clinicaltrials.gov) identifier [NCT02420535](https://clinicaltrials.gov/ct2/show/study/NCT02420535) (Date of registry: 4/20/2015, prior to the start of the clinical trial).

Keywords: Neuropsychiatric symptoms of dementia, Non-pharmacologic strategies, informal caregivers

* Correspondence: kales@umich.edu

¹Program for Positive Aging, Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Box 5765, Ann Arbor, MI 48109, USA

²Department of Veterans Affairs, HSR&D Center for Clinical Management Research (CCMR), Ann Arbor, MI, USA

Full list of author information is available at the end of the article



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Dementia currently affects over 5 million people in the US, and with the aging of the population is projected to affect 16 million people by 2050. While cognitive impairment is the clinical hallmark of dementia, non-cognitive behavioral and psychological symptoms (BPSD) are nearly universal (affecting 98% of individuals at some point in the illness course) and often overshadow cognitive symptoms in the disease course [1].

BPSD occur in dementias of all types and include depression, psychosis, psychomotor agitation, aggression, apathy, sleep disturbances, and inappropriate behaviors [2]. While BPSD can be thought of as the consequence of the neurodegeneration associated with dementia, they are triggered by multiple interacting factors internal and external to the person with dementia. These include patient (e.g. undiagnosed medical conditions and untreated pain), caregiver (e.g. ineffective communication style) and environmental (e.g. overstimulation or lack of activity/structure) factors [3]. Importantly, many of these triggers are modifiable.

There are 15 million family caregivers of people with dementia in the US. Clinicians depend on caregivers to assess and manage BPSD in the community including reporting on symptoms, carrying out recommendations, and evaluating the effect of treatment. As opposed to core cognitive symptoms, managing BPSD is one of the most challenging aspects of care, causing intense caregiver burden and upset [4]. Caregivers of individuals with BPSD are more distressed and depressed than those not managing behaviors [5]. There is emerging evidence that caregiver distress associated with BPSD is a more important predictor of institutionalization and inpatient and emergency department use than the frequency and severity of the BPSD themselves [6–9]. Thus, it is not surprising that BPSD are associated with a multitude of negative outcomes such as hospital stays, injuries, caregiver stress and depression, reduced caregiver employment income, earlier nursing home placement as well as higher patient mortality [3]. BPSD are also costly, with BPSD management accounting for 30% of the cost of caring for community-dwelling people living with dementia (PLWD) [10]. Recent research suggests that managing BPSD can lower costs of dementia care for families.

Unfortunately, few treatment options are currently available to family caregivers for BPSD. Typically, if a caregiver expresses concern about a BPSD to a physician, a psychiatric medication is prescribed to control the symptom. However, this is an ineffective and potentially dangerous strategy for several reasons: 1) the risk/benefit profiles of psychiatric medications for dementia are poor [11, 12]; and 2) BPSD are a “moving target” with different symptoms appearing over time and

caregivers often managing multiple BPSD simultaneously. Unpredictability and complexity make a simple “magic bullet” medication solution impossible [13].

In contrast, nonpharmacologic strategies are recommended by multiple medical organizations and expert groups as the preferred first-line treatment approach to BPSD, except in emergency situations when behaviors could lead to imminent danger [14–16]. With an emerging evidence base, nonpharmacologic behavioral management strategies are increasingly recognized as a critical part of comprehensive, state of the art dementia care [15], with the common goals of symptom relief and reduction of caregiver distress. Currently, the best evidence base for non-pharmacologic approaches appears to rest with interventions for family caregivers [3] including Resources for Enhancing Alzheimer’s Caregiver Health (REACH II) [17], the Tailored Activity Program (TAP) [18] and the Care of Persons with Dementia in their Environments (COPE) [19], and the Advancing Caregiver Training (ACT) study [20]. In this type of approach, problem solving with a family caregiver to identify triggers or modifiable underlying causes of BPSD is combined with the use of selected non-pharmacologic strategies.

However, such approaches have largely not been translated to real-world care and clinical settings likely because they are “hands-on” staff- and training-intensive interventions. Such approaches have effectiveness, but require training and are time-consuming. Therefore, it is not surprising that: 1) few have been translated into a widely deliverable and sustainable approach, and 2) family caregivers continue to be underserved or receive services that are not evidence-based. Further, as families need assistance managing BPSD in real time, technologies and online platforms may be better able to deliver ‘on demand’ support [21]. While a number of prior studies have incorporated technology components [22–25], we know of no web-based, easy to use, comprehensive interactive tools to help family caregivers manage BPSD and track their modifiable underlying causes such as pain, infection, communication problems or environmental overstimulation including which strategies were effective.

We sought to overcome this research-practice gap by creating a web-based tool for family caregivers that would guide them through a clinical reasoning process to identify, monitor and manage behaviors while simultaneously addressing their motivation, self-efficacy and problem-solving skills. This approach has previously been applied to the management of complex health conditions such as cancer and asthma, or to assist with smoking cessation and weight management [26, 27].

The bedrock of the tool is the “DICE” approach to BPSD that was developed from a US national multidisciplinary expert consensus panel [28]. DICE™ (hereafter abbreviated as DICE) is an algorithmic, evidence-based approach

comprising four steps: DESCRIBE: describe the behavior to derive an accurate characterization and the context in which it occurs; INVESTIGATE: examine, exclude and identify possible underlying causes of the behavior; CREATE: create and implement a treatment plan for the behavior; and EVALUATE: assess what parts of the treatment plan were attempted and effective. Within the DICE approach caregiver (expectations, caregiver stress/depression, etc), PLWD (medical conditions, functional status, etc); and environmental (overstimulation, lack of routines, etc) contributions to BPSD are evaluated and addressed.

This project had three phases. In the first, we involved end-users (e.g. family caregivers) in the design of a web-based tool incorporating DICE that would: 1) be easy to use; 2) be tailored to the PLWD and caregiver's specific behavioral concerns, environment and personal characteristics; 3) teach new transferrable skills to the end-users; 4) provide an alternative to the risks and limited efficacy associated with medication treatment; and 5) could be used throughout the disease course. In the second phase, we engaged in iterative cycles of programming, testing and refinement to translate evidence-based treatment and knowledge into a usable tool (called the WeCareAdvisor). These two phases are described in detail in other manuscripts [29, 30].

In the third phase, we assessed the WeCareAdvisor tool (WCA) with family caregivers in a pilot randomized controlled trial (RCT) to evaluate its one-month effect on caregiver distress and caregiver confidence as compared to a waitlist control group. A one-month time frame for tool use was selected as appropriate for this pilot/proof of concept study. Secondary outcomes included caregiver stress, depression, burden, negative communication and relationship closeness, and PLWD behavioral frequency and severity. This paper reports the outcomes of the RCT including effects following one-month of tool use between an immediate treatment group (WCA) and a wait-list control group and then within group differences for the WCA and Waitlist control groups following their one month tool use.

Methods

A two-site randomized controlled trial was conducted with one-month intervention and follow-up after baseline assessment targeting family caregivers of people with dementia. The design of the trial is detailed in a prior manuscript [30]. All three phases of the project were approved in 2012 by Institutional Review Boards of University of Michigan and Johns Hopkins University. This study adhered to CONSORT guidelines.

Recruitment and eligibility

Participants were consecutively recruited beginning in May 2015 through September 2016. They were recruited from community and outpatient clinical sites in Ann

Arbor, Michigan and Baltimore, Maryland by several methods: provider or staff referral; on-site by research staff; caregiver response to flyers in a participating site; or participation in a previous trial. Interested caregivers were screened for eligibility by telephone. Inclusion criteria included: primary caregiver for a PLWD (clinical diagnosis or MMSE < 24); residing with the PLWD or close by; managing ≥ 1 behavioral symptom; English speaking; and familiarity with technology (computer, tablet or smartphone). Exclusion criteria included: caregiver sensory impairment; and for the person with dementia: imminent institutional placement, terminal illness, active suicide risk, or not on a stable dose of psychotropic for at least 60 days. Figure 1 depicts recruitment and study flow.

Procedures

Eligible caregivers were next scheduled for a baseline in-home interview. Written consent from the caregiver and the PLWD were obtained at that time, including the fact that subjects could withdraw from the study at any point in time. If the PLWD was unable to provide informed consent, then proxy consent from the family caregiver (and assent from the person with dementia) was obtained. At the conclusion of the baseline interview, the interviewer opened a randomization envelope determining group assignment. Those randomized to the Waitlist control group (1-month wait) were informed of their assignment and an appointment in one-month was scheduled. Those assigned to receive the WeCareAdvisor immediately (intervention) received: 1) an iPad with the WeCareAdvisor website link; 2) optional email account setup (if no prior email access); and 3) approximately 15-min instruction in use of the tool.

Two to three days after the baseline visit and thereafter weekly during the one-month of the intervention, participants received a "check-in" phone call from a study team member. The purpose of this call was to trouble shoot problems with the tool and encourage tool use. These calls were not of a clinical nature; staff used a guiding script for the purpose of this call in order to anchor it around the tool, and limited the length of calls to a maximum of 20 min.

One month after baseline, an in-home follow-up interview was completed with both intervention and control participants. For intervention participants, after outcome assessment, the interviewer collected the iPad and their study participation was concluded. For Waitlist controls, identical procedures were followed as for the intervention group at baseline, and this group began their one month of tool use and was reassessed one month later.

Randomization

A randomization table was created by the University of Michigan statistician in Stata, stratified by study site and




Fig. 1 Consort Flow Diagram

using random blocks of sizes 4,6 or 8, and provided to a project manager at each site who was not involved in assessment. The project manager created sequentially numbered sealed envelopes containing group assignment. Each consenting caregiver received the envelope in the order in which they were enrolled. The project manager had access to the spreadsheet that indicated the randomization order but the research assistants who performed baseline and outcome assessments were masked as to randomized condition.

Baseline assessments

Comprehensive assessments were performed to collect data from caregivers and people with dementia on several domains including: 1) demographics; and 2) physical and mental health related characteristics; 3) and technology experience (caregiver only). Primary and secondary outcomes are below.

Primary and secondary outcomes

The primary study aim was to evaluate the extent to which WCA impacted caregiver distress (measured by

the total of the distress items from a revised version of the NPI-Q; in the revised version, we separated agitation and aggression and added frequency for a total of 14 items, score range 0–70) and confidence in using activities to manage BPSD (five item scale, score range 0–50) after one month of use. Caregiver distress was selected as the primary outcome based on emerging evidence that it may be a more important predictor of institutionalization and inpatient and emergency department use than the frequency and severity of the BPSD themselves [6–9]. We expected that after one month of WCA use, the intervention group would report less distress and greater confidence than those in the Waitlist control group. We also expected that the Waitlist group would experience similar benefits following their one month of tool use.

Secondarily, we evaluated change in caregiver stress (five-point likert scale ranging from 1 to 5), depression (CES-D, 20 items, score range 0–60), burden (Zarit burden scale, 12-item, score range 12–60), negative communication (Negative Communication Scale, 6 items, score range 6–30) and relationship closeness (Relationship

Closeness Scale, 6-item, score range 6–24) and PLWD behavioral frequency, severity, and total behavioral score (NPI-Q revised version, separating agitation and aggression and adding frequency as in the NPI-C). Secondary measures were chosen based upon those that are both meaningful in clinical practice as well as appear to be impacted by family caregiver interventions in prior trials [18–20]. For a full description of measures, please see the WeCareAdvisor protocol paper [30].

Intervention/components of the WeCareAdvisor tool

For a full description of the tool, please refer to the prior paper describing its development [29]. Briefly, the tool contains three main components.

- The first is a guided DICE approach where a peer navigator (tailored to the age, race and gender of the caregiver) leads the caregiver through the approach; this occurs through the caregiver answering questions related to symptom context (who, what, when, where) and possible medical/pain issues including delirium. Based upon these answers, an algorithm selects from over 900 evidence-based strategies to create a WeCareAdvisor “prescription”. Caregivers are instructed to try the strategies for one week and then evaluate how the strategies work for them; if the strategies are helpful, they are encouraged to keep using them, if the strategies have not been helpful, caregivers are encouraged to conduct another DICE session to get a new set of strategies. During orientation, caregivers conducted their first DICE session on the most problematic behavior they were experiencing, and during their one-month trial were encouraged to create as many sessions as they feel would be helpful to them.
- The second component is the Caregiver Survival Guide which is a compendium of information for dementia caregivers (e.g. “what is dementia”, “keeping the person with dementia healthy”) located in one place for “one stop shopping”.
- The third component is a daily messaging feature that provides an encouraging daily communication to caregivers for support and motivation.

Analytic approach

Data management and analyses were coordinated at the University of Michigan for both sites. For all outcome measures, summary descriptive statistics were calculated at baseline and one month, for change scores from baseline to one month by study group, and by site for one month to two months (for the Waitlist control group). WCA-associated change was estimated in a regression model with change-scores from baseline to one month as the dependent variable, and an indicator for the intervention

group as the primary independent variable. The model adjusted for baseline values of the outcome variable (e.g. for change in confidence, adjustment for baseline confidence) and site (Ann Arbor vs. Baltimore). The parameter estimate of the intervention group indicator allowed for testing of the WCA effect on distress (or confidence) and estimated expected changes in scores associated with the tool, adjusting for baseline values. Due to presence of two participants with missing follow-up data, to obtain unbiased estimates, we also used a mixed model and obtained an estimate associated with the tool by fitting a multilevel model with both baseline and follow-up data as dependent variables. The model included random intercepts for participants, site, time, WeCare group, and time by WeCare group interaction term. Because the Waitlist controls received the tool after a one-month delay, their change data from one to two months was used to estimate additional effects in this group. We also compared intervention to waitlist changes in caregiver stress, depression, burden, negative communication, and relationship closeness as well as in the frequency, severity and total score for behavioral symptoms in PLWD.

Power consideration

Although this was a proof of concept and feasibility Phase II trial, our proposed sample size of 30 dyads in each study group ($n = 60$ total) was calculated to afford 80% power, based on a two-group 0.05 significance level test, to detect a standardized effect size of 0.725, and the margin of error for the effect size estimate with 95% confidence calculated to be ± 0.51 standard deviation.

Results

Of 131 potential participants screened across the two sites, 74 caregivers were eligible. Of eligible caregivers, 57 (77.02%) were willing to participate. A total of 55 (96.5%) completed followup. The mean age of caregivers was 65.9 ± 14.0 years old and the majority (75%) were female. Most (84%) had more than a high school education and the majority (74%) were married and white (63%). Almost half (49%) were spouses. Caregivers had a mean of 4.1 ± 3.1 medical and 0.4 ± 0.6 mental health conditions. Regarding PLWD, their mean age was 80.4 ± 10.2 years old, most were female (63%), married (58%), and white (65%). The mean MMSE was 16.5 ± 8.3 , the mean number of NPI behaviors 7.3 ± 3.1 and the mean level of functional dependence 9.9 ± 4.3 .

Table 1 shows baseline (T0) demographic characteristics for caregivers and the PLWD in the WCA and Waitlist control groups. A Wald χ^2 test from a logistic regression controlling for site indicated there were no significant demographic differences between the two study groups. Table 2 lists other characteristics for caregivers and the PLWD showing no significant differences between the

Table 1 Basic Demographic Characteristics (N = 57)

	WeCare ^a (N = 27)		Waitlist ^a (N = 30)		p-value ^b
Caregiver	N	(%)	N	(%)	
Age, Mean ± S.D.	65.5 ± 11.8		66.2 ± 15.9		0.882
Male	8	[29]	6	[19]	0.405
Education ^a					
< =High School /GED	4	[15]	5		0.858
> High School	23	(85)	25	(83)	
Marital Status ^a					
Single	10	(37)	5		0.087
Married	17	(63)	25	(83)	
Race ^a					
White	17	(63)	19	(63)	0.788
African American	8	[29]	10	(33)	
Other	2	[7]	1	[3]	
Person with Dementia is Spouse ^a	13	(48)	15	(50)	0.870
No. Physical Chronic Conditions (0–24) ^c	4.2 ± 3.4		4.1 ± 2.9		0.906
No. Mental health diagnoses (0–5) ^d	0.3 ± 0.6		0.5 ± 0.6		0.310
Person with Dementia					
Age, Mean ± S.D.	82.3 ± 9.3		78.6 ± 10.8		0.102
Male	8	[29]	13	(43)	0.286
Marital Status ^a					
Single	13	(48)	11	(37)	0.374
Married	14	(52)	19	(63)	
Race ^a					
White	18	(67)	19	(63)	0.706
African American	7	[25]	10	(33)	
Other	2	[7]	1	[3]	
MMSE (0–30), Mean ± S.D.	15.0 ± 8.5		18.0 ± 8.0		0.091
No. of Behaviors ^e (0–14), Mean ± S.D.	7.6 ± 3.0		7.0 ± 3.3		0.462
Functional Dependence ^f (0–15), Mean ± S.D.	10.4 ± 4.5		9.5 ± 4.1		0.378

^aCategories are collapsed^bFor between study arm difference controlling for site^cCount out of 24 systemic illnesses and conditions^dCount out of 5 mental health diagnoses^eNumber of presence of 14 NPI symptoms^fNumber of assistance needed in 15 daily function items^gOne subject dropped in follow-up

groups with the exception of caregiver confidence in using activities to manage behaviors that was significantly higher at baseline in the Waitlist group, based on a Wald χ^2 test from a logistic regression controlling for site.

We examined demographic and other characteristics by study site using t-tests for continuous variables and χ^2 tests for categorical variables (Ann Arbor vs. Baltimore) where

several significant differences were noted: caregiver age (mean of 62.0 ± 14.3 in Ann Arbor vs. 69.4 ± 12.9 in Baltimore, $p = 0.04$), PLWD age (Ann Arbor mean 75.1 ± 10.2 vs. Baltimore mean 85.1 ± 7.5 , $p < 0.001$), MMSE (Ann Arbor mean 19.7 ± 7.6 vs. Baltimore mean 14.1 ± 8.2 , $p = 0.02$) and functional dependence (Ann Arbor mean 8.0 ± 4.4 vs. Baltimore mean 11.6 ± 3.4 , $p = 0.001$).

Table 2 Baseline Characteristics of Caregiver and Person with Dementia (N = 57)

	WeCare (N = 27)	Waitlist (N = 30)	p-value ^a
Caregiver	N	N	
Confidence in Using Activities (5 items; 0–50) ^b	35.0 ± 10.0	39.7 ± 6.9	0.044
Technology Experience ^c	9.3 ± 1.0	8.8 ± 1.4	0.146
Caregiver Distress (14 items; 0–70) ^d	18.0 ± 10.7	15.4 ± 10.7	0.372
Caregiver Stress (1–5) ^d	3.0 ± 1.2	2.8 ± 1.1	0.586
CES-D for Depression (20 items; 0–60) ^d	12.6 ± 8.9	12.6 ± 7.5	0.984
Burden (12 items; 12–60) ^c	31.9 ± 7.3	31.2 ± 8.2	0.743
Negative Communication (6 items; 6–30) ^d	11.5 ± 3.4	11.8 ± 3.5	0.701
Relationship Closeness (6 items; 6–24) ^d	17.3 ± 4.7	17.6 ± 4.4	0.867
Caregiver Readiness (17 items; 17–68) ^d	59.0 ± 5.6	57.1 ± 6.8	0.253
Person with Dementia			
Overall Physical Health (1–5) ^e	3.2 ± 1.2	3.1 ± 1.2	0.729
No. of Health Assessment (of 25 Systemic Illnesses and Conditions; 0–25)	6.2 ± 3.0	6.0 ± 3.3	0.854
Behavior Frequency (14 items; 0–56) ^f	18.8 ± 8.8	15.4 ± 9.1	0.164
Behavior Severity (14 items; 0–42) ^f	12.8 ± 7.7	10.4 ± 6.4	0.224

^aFor between study arm difference controlling for site^bCan range 0–50; 5 items, each 0–10. Higher scores correspond to greater confidence^cCan range from 0 to 10; use of computer, internet, cell phone, microwave oven, copier, ATM, self-checkout at grocery store, audio books, digital camera, and programmable devices (e.g. coffee maker, thermostat)^dHigher scores correspond to greater distress, stress, depressive symptoms, burden, negative communication, closeness, or readiness, respectively^eExcellent [5], Very Good [4], Good [3], Fair [2], Poor [1]^fHigher scores correspond to greater frequency or severity, respectively

Tool use

Table 3 shows the heterogeneity of behaviors that caregivers used the WCA for during the trial. The most common behavior caregivers created DICE sessions for was agitation (17.5%) followed by toileting (12.3%), aggression (10.5%), and anxiety (10.5%). DICE sessions were created for all 10 other behaviors but in fewer than 10% of caregivers each.

One-month Followup outcomes

Table 4 presents the results of unadjusted followup outcomes.

Within group outcomes baseline to one month (T0-T1)

Based on a t-test, within the group that immediately received the WeCareAdvisor tool, distress declined significantly after their one month of tool use (6.08 ± 6.31 points, $t = -4.82$, $p < 0.0001$); confidence increased after

tool use, but this increase was not significant (1.00 ± 11.44 points, $t = 0.45$, $p = 0.66$). The frequency of behaviors (−3.60 ± 5.05 points, $t = -3.56$, $p = 0.002$), severity of behaviors (−3.24 ± 3.87 points, $t = -4.19$, $p = 0.0003$) and NPI score (−6.80 ± 10.73 points; $t = -3.17$, $p = 0.004$) were all significantly decreased in the WCA group after one month of tool use. Distress ($t = -4.51$, $p < 0.001$), behavioral frequency ($t = -3.31$, $p = 0.0014$), severity ($t = -3.76$, $p = 0.0003$) and NPI score ($t = -2.53$, $p = 0.0132$) all remained significant after adjustment for site. In the same timeframe, Waitlist control caregivers showed a significant worsening (decrease) in confidence (−6.40 ± 10.30, $t = -3.40$, $p = 0.002$).

Between group comparisons

Caregiver distress At one-month follow-up (T1), a χ^2 test showed the WCA group had a higher percentage of

Table 3 Behaviors Targeted by Caregivers in DICE Sessions

Behavior targeted in DICE sessions	Number of caregivers	PERCENT
Agitation	10	17.5
Toileting	7	12.3
Aggression	6	10.5
Anxiety	6	10.5
Apathy	5	8.8
Appetite and Eating	5	8.8
Motor Disturbance	5	8.8
Delusions	3	5.3
Irritability	3	5.3
Nighttime Behaviors	3	5.3
Depression	2	3.5
Disinhibition	1	1.8
Hallucinations	1	1.8

caregivers with improvement in distress (number of caregivers who had any improvement in distress from T0 to T1 divided by the total number of caregivers in the group) over the Waitlist control group (73.1% vs. 46.7%, $\chi^2 = 4.01$, $df = 1$, $p = 0.04$). Unadjusted analyses using a t-test showed that the WCA group had a greater decline in distress compared to the Waitlist control group ($t = -2.49$, $p = 0.02$). Results remained significant after adjusting for site and baseline distress in a regression model (beta = -3.71 , $p = 0.02$) and in a mixed model (beta = -4.45 , $p = 0.02$).

Caregiver confidence At one-month follow-up (T1), the WCA group had a higher percentage of caregivers with improvement in confidence over the Waitlist control group (42.3% vs. 26.7%), however this difference was not significant based on a χ^2 test ($\chi^2 = 1.52$, $df = 1$, $p = 0.22$). In unadjusted analyses, the WCA group had a significantly greater change in confidence than the Waitlist control group ($t = 2.55$, $p = 0.01$); note that this difference did not indicate significant improvement in confidence in the WCA group, but rather worsening confidence in the Waitlist group. The difference was not significant in a regression model after adjusting for site and baseline level of confidence (beta = 4.48 , $p = 0.09$), however, remained significant in mixed model (beta = 7.52 , $p = .004$).

Caregiver stress, depression, burden, negative communication, relationship closeness No differences between study groups in these outcomes were found in unadjusted and adjusted analyses using both regression and mixed model.

Person living with dementia behavioral outcomes There were no significant differences in behavioral

frequency, severity or overall NPI score (frequency by severity) between the WCA and Waitlist groups at one-month followup based on t-tests and in regression and mixed models.

Waitlist control one-month within group outcomes (T1-T2)

A t-test indicated that the Waitlist control group showed significant improvement in both primary outcomes after their one month (T1 to T2) of tool use: distress significantly decreased (3.72 ± 7.53 points, $t = -2.66$, $p = 0.013$) and confidence significantly improved (4.38 ± 5.17 points, $t = 4.56$, $p < 0.0001$). This group also showed improvement in stress (-0.41 ± 1.02 points, $t = -2.19$, $p = 0.04$), caregiver burden (-2.76 ± 7.26 points, $t = -2.05$, $p = 0.05$), and negative communication (-1.48 ± 2.96 points, $t = -2.70$, $p = 0.012$). PLWD in the Waitlist group also showed a significant reduction in frequency of behaviors (-1.86 ± 4.58 points, $t = -2.19$, $p = 0.037$) and trend-level reductions for severity of behaviors (-1.45 ± 4.50 points, $t = -1.73$, $p = 0.09$) and overall NPI score (-5.00 ± 14.34 points, $t = -1.88$, $p = 0.07$).

The significant decline in distress between T1 and T2 for the Waitlist control group remained significant after adjustment for site in a mixed model (beta = -3.83 , $p = 0.004$) as did the significant improvement in confidence (beta = 4.67 , $p = 0.009$). However, stress (beta = -0.43 , $p = 0.06$) and the decrease in frequency of behaviors was not significant after adjustment for site in a mixed model (beta = -1.90 , $p = 0.075$).

Figure 2a shows the pattern for caregiver distress for the two study groups over the trial. Figure 2b shows the pattern for caregiver confidence for the two study groups over the trial. Figure 2c, d and e show behavioral frequency, severity and overall NPI score for the two groups across the trial.

Discussion

In this pilot RCT, we tested a novel web-based tool to help caregivers manage BPSD on caregiver distress and confidence over a one-month period. Use of the WCA was associated with significant declines in caregiver distress in the primary comparison of the intervention group vs. the waitlist control group, as well as after the waitlist control group completed one month use of the tool. The impact on caregiver confidence was less clear, with unadjusted differences reflecting worsening of confidence in the control group. Interestingly, however, once the control group completed their use of the tool, they showed improvement in confidence that remained after adjustment. While PLWD behavioral frequency, severity, and overall NPI score were null in the primary comparison of the WCA vs. Waitlist group, within group comparisons showed improvement with use of the tool (for the WCA group, frequency, severity and total

Table 4 Change from Baseline to Follow-up in Caregiver and Person with Dementia Measures

	Change from Baseline to Month 1 (value at month 1- value at baseline)							Change from Month 1 to Month 2 (value at month 2- value at month 1)			
	WeCare (n=26 ^a)			Waitlist (N = 30)			Test for group difference in change (WeCare-Waitlist)		Waitlist (N=29 ^b)		
	Mean Change ± S.D.	t-value	p-value	Mean Change ± S.D.	t-value	p-value	t-value	p_value	Mean Change ± S.D.	t-value	p-value
Caregiver											
Confidence in Using Activities (5 items; 0–50) ^d	1.00 ± 11.44	0.45	0.660	−6.40 ± 10.30	−3.40	0.002	2.55	0.014	4.38 ± 5.17	4.56	<.0001
Caregiver Distress (14 items; 0–70) ^d	− 6.08 ± 6.31	−4.82	<.0001	−1.80 ± 6.36	−1.55	0.132	− 2.49	0.016	−3.72 ± 7.53	− 2.66	0.013
Caregiver Stress (1–5) ^d	0.12 ± 1.66	0.36	0.726	0.17 ± 0.99	0.93	0.362	−0.14	0.891	−0.41 ± 1.02	− 2.19	0.037
CES-D for Depression (20 items; 0–60) ^d	− 2.08 ± 5.87	−1.77	0.089	− 0.47 ± 7.13	− 0.36	0.723	−0.90	0.370	−0.55 ± 8.63	−0.34	0.733
Burden (12 items; 12–60) ^d	− 1.72 ± 6.91	−1.25	0.225	1.30 ± 6.38	1.12	0.274	−1.68	0.098	− 2.76 ± 7.26	−2.05	0.050
Negative Communication (6 items; 6–30) ^d	− 1.04 ± 3.56	−1.46	0.158	0.77 ± 3.62	1.16	0.255	−1.86	0.069	−1.48 ± 2.96	−2.70	0.012
Relationship Closeness (6 items; 6–24) ^d	0.36 ± 2.33	0.77	0.446	−0.37 ± 4.31	− 0.47	0.645	0.79	0.431	1.07 ± 3.30	1.72	0.097
Person with Dementia											
No. of Behaviors ^e (0–14)	−1.62 ± 1.77	− 4.66	<.0001	−0.93 ± 2.15	−2.38	0.024	−1.28	0.204	−0.38 ± 1.82	− 1.12	0.272
Behavior Frequency (14 items; 0–56) ^f	− 3.60 ± 5.05	−3.56	0.002	−1.90 ± 5.63	−1.85	0.075	−1.17	0.248	−1.86 ± 4.58	− 2.19	0.037
Behavior Severity (14 items; 0–42) ^f	− 3.24 ± 3.87	−4.19	0.0003	− 1.47 ± 4.04	−1.99	0.056	−1.65	0.104	−1.45 ± 4.50	−1.73	0.094
NPI Score ^f (frequency x severity)	−6.80 ± 10.73	−3.17	0.004	−3.20 ± 10.67	−1.64	0.111	−1.24	0.220	−5.00 ± 14.34	− 1.88	0.071

^aOne subject dropped in Month-1 follow-up^bOne subject dropped in Month-2 follow-up^cCan range 0–50; 5 items, each 0–10. Higher scores correspond to greater confidence^dHigher scores correspond to greater distress, stress, symptoms, burden, negative communication, or closeness, respectively^eNumber of presence of 14 NPI symptoms^fHigher scores correspond to greater frequency, severity, or score, respectively

behavioral scores; for the Waitlist group, trend-level improvement in behavioral frequency).

The impact of the WeCareAdvisor on caregiver distress suggests that it could have a role in caregiver management of BPSD. Emerging evidence suggests that the impact of behaviors on caregivers, manifested as distress, is an important predictor of negative outcomes. Philp et al. found that among 114 community-dwelling Scottish people with dementia supported by family carers followed for 2 years, caregiver perceptions of a behavior as problematic rather than severity of a behavior independently predicted institutionalization [9]. In a second study of 119 Dutch PLWD and their caregivers followed over five years, caregiver distress (measured using the NPI as in the present study) itself was a significant

predictor of nursing home placement while behavior itself was not [8]. The authors noted that their findings could indicate that a caregiver's emotional reaction to a particular behavior was more important than the behavior per se in the decision to admit the person with dementia to a nursing home. A meta-analysis of BPSD and outcomes concluded that caregiver factors are more important than care-recipient factors in predicting institutionalization [6]. A recent analysis using retrospective, nationally representative data of participants with dementia from the Aging, Demographics and Memory study found that high levels of caregiver distress (rather than the BPSD themselves) were significantly associated with emergency department visits, hospitalizations, and costs [7]. Cumulatively, this




Fig. 2 Change in Caregiver Distress and Confidence and PLWD Behavioral Frequency, Severity and NPI Total Score Over Time

evidence suggests that identifying and supporting caregivers in distress is a worthy target in reducing the negative outcomes associated with BPSD.

Notably, outcomes related to caregiver confidence were less clear. In part, this may be related to the higher baseline level of mean confidence in the control group. Another factor may be the confidence measure used in this trial (that assesses confidence in using activities to manage BPSD). This measure has been used in prior studies of caregiver interventions related to the use of tailored activities [18, 31]. While WeCareAdvisor applies a number of strategies involving use of activity to manage some symptoms (e.g., agitated outbursts), activity may be less relevant for other problems (e.g. for certain toileting problems). While agitation was the most common problem behavior for which caregivers created DICE sessions, the second most common was toileting; in these cases, confidence using activities is an imperfect measure. Thus, it is possible that this measure was not sensitive to the broad array of behaviors that family caregivers in this study were managing.

Similarly, while the findings for behavior change trended in a promising direction, there was no significant impact of WCA use on severity or frequency of BPSD as compared to the control group in the primary comparison. There may be several reasons for this. First, we did not select for any behaviors (e.g. agitation) like other trials and therefore heterogeneity (with behaviors ranging from agitation to apathy to eating issues, etc) may have impacted results. Second, one month may not be enough time to impact behavioral outcomes; notably most drug trials in BPSD are 8–10 weeks. These aspects of our trial may have impacted the ability to effect overall stress level, depression, caregiver burden, negative communications or relationship closeness.

Strengths of the study include development of a low cost, easy to use, on-demand web-based intervention for caregivers to address BPSD, developed with extensive end-user feedback. Another strength is that the tool is based upon the DICE Approach which emphasizes the importance of looking for underlying causes (e.g. pain, UTI) with symptoms like agitation. A final strength is that this was a controlled trial with dyadic outcomes which are critical in the evaluation of impact on BPSD. Weaknesses include a control group with limited attention and support (e.g. the intervention group received about 1 h more of staff contact via weekly check-in calls about tool use over 1 month) and positive outcomes in the primary comparison limited to caregiver distress. While this small pilot RCT demonstrates feasibility and a promising impact on caregiver distress, the size of and limitations inherent in this study limit generalizability. A future study will include a longer (three month) trial with a larger more diverse sample including attention to

whether the weekly check-in calls are necessary or whether email prompts are sufficient. A long-term care version of the tool is also currently being tested in Veterans Administration Community Living Center (nursing home) facilities.

Conclusions

In our pilot RCT, use of the WCA resulted in significant decrease in caregiver distress. Prior research has shown that caregiver distress is an important predictor of negative BPSD outcomes including ED visits, hospitalizations and nursing home placement. Future research will identify whether longer use of WCA can significantly impact other caregiver and behavioral outcomes.

Abbreviations

BPSD: Behavioral and psychological symptoms of dementia; CES-D: Center for Epidemiologic Studies Depression scale; DICE: Describe, Investigate, Create, Evaluate; NPI: Neuropsychiatric Inventory; PLWD: Person living with dementia; RCT: Randomized controlled trial; T0: Baseline; T1: One-month followup; T2: One-month follow-up post tool for Waitlist control group; WCA: WeCareAdvisor

Acknowledgements

Findings from the study were presented in part at the American Association for Geriatric Psychiatry Annual Meeting, Dallas TX, March 27, 2017 and at the Alzheimer's Association International Conference, London England, July 16, 2017. Copyright for DICE™ and WeCareAdvisor™ are held jointly by University of Michigan and Johns Hopkins University (Copyright 2015 The Regents of the University of Michigan and Johns Hopkins University).

Funding

This research was supported by a grant from the National Institute of Nursing Research (NR014200-01) and grant P50AG005146 for the Johns Hopkins Alzheimer's Disease Research Center. The funding organization had no role in any of the following: design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

Availability of data and materials

The dataset used in the current study are not publicly available due to intellectual property restrictions with the WeCareAdvisor™ tool. Data are available from the authors under reasonable request and with permission of the University of Michigan and Johns Hopkins University.

Authors' contributions

HC = acquisition of funding, conception and design, acquisition of data, interpretation of data, drafting of manuscript, final approval of manuscript. LNG = acquisition of funding, conception and design, acquisition of data, interpretation of data, drafting of manuscript, final approval of manuscript. BS = acquisition of data; interpretation of data, revision of manuscript, final approval of manuscript. HMK = conception and design; analysis and interpretation of data, revision of manuscript, final approval of manuscript. KM = acquisition of data; interpretation of data, revision of manuscript, final approval of manuscript. MT = acquisition of data; interpretation of data, revision of manuscript, final approval of manuscript. CC = analysis and interpretation of data, revision of manuscript, final approval of manuscript. CGL = conception and design; interpretation of data, revision of manuscript, final approval of manuscript.

Ethics approval and consent to participate

All three phases of the project were approved in 2012 by Institutional Review Boards of University of Michigan and Johns Hopkins University. Written consent was obtained from all caregiver-subjects, and from all PLWD-subjects who could provide informed consent. If the PLWD was unable to provide informed consent, then proxy consent from the family caregiver (and assent from the person with dementia) was obtained.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests with the exception of CGL:

C.G.L. receives grant support (research or CME) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation. He is also Consultant/Advisor to Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Astellas. He also receives Honorarium or travel support from Pfizer, Forest, Glaxo-Smith Kline, Health Monitor.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Program for Positive Aging, Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Box 5765, Ann Arbor, MI 48109, USA. ²Department of Veterans Affairs, HSR&D Center for Clinical Management Research (CCMR), Ann Arbor, MI, USA. ³Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. ⁴Department of Community Public Health, School of Nursing, Johns Hopkins University, Baltimore, MD, USA. ⁵Division of Geriatrics and Gerontology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. ⁶Center for Innovative Care on Aging, Johns Hopkins University, Baltimore, MD, USA. ⁷Center for Statistical Consultation and Research, University of Michigan, Ann Arbor, USA. ⁸Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview and Johns Hopkins University, Baltimore, MD, USA.

Received: 20 September 2017 Accepted: 30 April 2018

Published online: 10 May 2018

References

1. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA*. 2005;293(5):596–608.
2. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. *Alzheimers Dement*. 2011;7(5):532–9.
3. Kales HC, Gitlin LN, Lyketsos CG. State of the art review: assessment and management of behavioral and psychological symptoms of dementia. *BMJ: British Medical Journal*. 2015;350.
4. Van Den Wijngaert MA, Vernooij-Dassen MJ, Felling AJ. The influence of stressors, appraisal and personal conditions on the burden of spousal caregivers of persons with dementia. *Aging Ment Health*. 2007;11(6):626–36.
5. de Vugt ME, Stevens F, Aalten P, et al. Do caregiver management strategies influence patient behaviour in dementia? *International journal of geriatric psychiatry*. 2004;19(1):85–92.
6. Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. *Int Psychogeriatr*. 2004;16(03):295–315.
7. Maust DT, Kales HC, McCammon RJ, Blow FC, Leggett A, Langa KM. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. *Am J Geriatr Psychiatry*. 2017;25:1074–82.
8. de Vugt ME, Stevens F, Aalten P, Lousberg R, Jaspers N, Verhey FR. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. *Int Psychogeriatr*. 2005; 17(4):577–89.
9. Philp I, McKee KJ, Armstrong GK, et al. Institutionalization risk amongst people with dementia supported by family carers in a Scottish city. *Aging Ment Health*. 1997;1(4):339–45.
10. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling

- Alzheimer's disease patients. *International journal of geriatric psychiatry*. 2002;17(5):403–8.
11. Schneider L, Tariot P, Dagerman K, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *New England Journal of Medicine*. 2006;355(15):1525–38.
 12. Maust DT, Kim HM, Seyfried LS, et al. Number needed to harm for antipsychotics and antidepressants in dementia. *Am J Geriatr Psychiatry*. 2014;22(3):S119–20.
 13. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. *JAMA*. 2012;308(19):2020–9.
 14. Workgroup C. Guideline for Alzheimer's disease Management—final report. In: State of California DoPH, ed2008.
 15. Odenheimer G, Borson S, Sanders AE, et al. Quality improvement in neurology: dementia management quality measures. *Neurology*. 2013;81:1545–154.
 16. NICE-SCIE Supporting Caregivers and patients. London: British Psychological Society; 2011. <https://www.scie.org.uk/publications/misc/dementia/dementia-fullguideline.pdf?res=true>.
 17. Belle SH, Burgio L, Burns R, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. *Ann Intern Med*. 2006;145(10):727–38.
 18. Gitlin LN. Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. *Am J Geriatr Psychiatry*. 2008;16(3):229–39.
 19. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers. *JAMA*. 2010;304(9):983–91.
 20. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. *J Am Geriatr Soc*. 2010;58(8):1465–74.
 21. Lee E. Do technology-based support groups reduce care burden among dementia caregivers? A review. *Journal of evidence-informed social work*. 2015;12(5):474–87.
 22. Beauchamp N, Irvine AB, Seeley J, Johnson B. Worksite-based internet multimedia program for family caregivers of persons with dementia. *The Gerontologist*. 2005;45(6):793–801.
 23. Czaja SJ, Rubert MP. Telecommunications technology as an aid to family caregivers of persons with dementia. *Psychosom Med*. 2002;64(3):469–76.
 24. Dang S, Nedd N, Nair S, Roos B, et al. Utilization of TLC technology by dementia family caregivers. *The Gerontologist*. 2004;44(1):604.
 25. Eisdorfer C, Czaja SJ, Loewenstein DA, et al. The effect of a family therapy and technology-based intervention on caregiver depression. *Gerontologist*. 2003;43(4):521–31.
 26. Strecher VJ, McClure J, Alexander G, et al. The role of engagement in a tailored web-based smoking cessation program: randomized controlled trial. *J Med Internet Res*. 2008;10(5):e36.
 27. Joseph CL, Havstad SL, Johnson D, et al. Factors associated with nonresponse to a computer-tailored asthma management program for urban adolescents with asthma. *J Asthma*. 2010;47(6):667–73.
 28. Kales HC, Gitlin LN, Lyketsos CG. The Detroit expert panel on the a, Management of the Neuropsychiatric Symptoms of D. Management of Neuropsychiatric Symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. *J Am Geriatr Soc*. 2014;62(4):762–9.
 29. Kales HC, Gitlin LN, Lyketsos C. "WECARE ADVISOR": a clinical trial of a caregiver focused, IPAD administered algorithm to manage behavioral symptoms. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2016;12(7):P217.
 30. Gitlin LN, Kales HC, Marx K, Stanislawski B, Lyketsos C. A randomized trial of a web-based platform to help families manage dementia-related behavioral symptoms: the WeCareAdvisor™. *Contemporary Clinical Trials*. 2017; 62(Supplement C):27–36.
 31. Gitlin LN, Winter L, Earland TV, et al. The tailored activity program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential. *The Gerontologist*. 2009;49(3):428–39.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

